Amneal Pharmaceuticals, Inc.
AMRX
$17.25
$0.201.17%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 157.36M | 122.12M | 72.06M | 5.90M | 3.38M |
| Total Depreciation and Amortization | 194.29M | 206.60M | 223.57M | 240.48M | 245.36M |
| Total Amortization of Deferred Charges | 16.70M | 19.51M | 22.43M | 25.53M | 28.53M |
| Total Other Non-Cash Items | 277.04M | 245.83M | 226.45M | 226.22M | 150.68M |
| Change in Net Operating Assets | -444.62M | -288.22M | -204.52M | -170.37M | -76.87M |
| Cash from Operations | 200.78M | 305.84M | 339.99M | 327.76M | 351.08M |
| Capital Expenditure | -117.67M | -98.58M | -98.84M | -78.14M | -80.20M |
| Sale of Property, Plant, and Equipment | 715.00K | 1.57M | 2.09M | 1.38M | 1.38M |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | 7.01M | 7.01M |
| Other Investing Activities | -95.41M | -19.16M | -15.51M | -13.11M | -9.30M |
| Cash from Investing | -212.37M | -116.18M | -112.26M | -82.87M | -81.12M |
| Total Debt Issued | 2.94B | 2.84B | 2.92B | 2.92B | 218.00M |
| Total Debt Repaid | -2.71B | -2.72B | -2.81B | -2.86B | -393.82M |
| Issuance of Common Stock | 1.29M | 1.93M | 1.96M | 1.56M | 1.52M |
| Repurchase of Common Stock | -44.93M | -44.94M | -22.28M | -22.34M | -22.41M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -115.06M | -127.88M | -118.82M | -119.23M | -37.70M |
| Cash from Financing | 69.63M | -51.42M | -31.53M | -82.61M | -234.40M |
| Foreign Exchange rate Adjustments | -2.09M | -2.23M | -1.68M | -2.21M | -1.51M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 55.95M | 136.01M | 194.52M | 160.06M | 34.05M |